Mefloquine
Mefloquine (mefloquine) is a small molecule pharmaceutical. Mefloquine was first approved as Lariam on 1989-05-02. It is used to treat falciparum malaria, malaria, and vivax malaria in the USA. It is known to target adenosine receptor A1 and adenosine receptor A2a.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Mefloquine (discontinued: Lariam, Mefloquine)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mefloquine hydrochloride | ANDA | 2025-04-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| malaria | EFO_0001068 | D008288 | B54 |
| vivax malaria | EFO_0007445 | D016780 | B51 |
| falciparum malaria | EFO_0007444 | D016778 | B50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 5 | 10 | 20 | 11 | 15 | 54 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | 7 | 12 | 6 | 10 | 31 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | — | — | 1 | 1 | 1 | 3 |
| Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | 1 | 1 | — | 2 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 3 | 4 |
| Schistosomiasis haematobia | D012553 | EFO_0007530 | B65.0 | — | 1 | 1 | — | — | 2 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | 1 | 1 | — | — | 2 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | 1 | — | 1 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 1 | — | 1 | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 2 | — | — | 2 |
| Schistosoma haematobium | D012548 | — | — | — | — | 1 | — | — | 1 |
| Schistosoma mansoni | D012550 | NCBITaxon_6183 | — | — | — | 1 | — | — | 1 |
| Disease susceptibility | D004198 | — | — | — | — | 1 | — | — | 1 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | 1 | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parasitemia | D018512 | — | — | 1 | 1 | — | — | — | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | — | — | — | 1 |
| Vaso-occlusive crises | D000098644 | — | — | 1 | 1 | — | — | — | 1 |
| Leukoencephalopathies | D056784 | — | R90.82 | 1 | 1 | — | — | — | 1 |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | — | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug resistance | D004351 | — | Z16.30 | — | — | — | — | 1 | 1 |
| Coinfection | D060085 | — | — | — | — | — | — | 1 | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mefloquine |
| INN | mefloquine |
| Description | (-)-(11S,2'R)-erythro-mefloquine is an optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown. It has a role as an antimalarial. It is an enantiomer of a (+)-(11R,2'S)-erythro-mefloquine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1 |
Identifiers
| PDB | — |
| CAS-ID | 53230-10-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL416956 |
| ChEBI ID | 63681 |
| PubChem CID | 40692 |
| DrugBank | DB00358 |
| UNII ID | TML814419R (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Mefloquine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,487 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,675 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use